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Characterization of Jak, STAT and Src Interactions in Head and Neck Squamous 
Cell Carcinoma 
Reshma Jaseja, B.S. 
Supervisory Professor: Faye M. Johnson, M.D., Ph.D.  
Recurrence of Head and Neck Squamous Cell Carcinoma (HNSCC) is 
common; thus, it is essential to improve the effectiveness and reduce toxicity of 
current treatments. Proteins in the Src/Jak/STAT pathway represent potential 
therapeutic targets, as this pathway is hyperactive in HNSCC and it has roles in cell 
migration, metastasis, proliferation, survival, and angiogenesis. During short-term 
Src inhibition, Janus kinase (Jak) 2, and signal transducer and activator of 
transcription (STAT) 3 and STAT5 are dephosphorylated and inactivated.  Following 
sustained Src inhibition, STAT5 remains inactive, but Jak2 and STAT3 are 
reactivated following their early inhibition. To further characterize the mechanism of 
this novel feedback pathway we performed several experiments to look at the 
interactions between Src, Jak2, STAT5 and STAT3. 
We attempted to develop a non-radioactive kinase assay using purified 
recombinant Jak2 and Src proteins, but found that phospho-tyrosine antibodies 
were non-specifically binding to purified recombinant proteins.  We then performed 
in vitro kinase assays (IVKAs) using purified recombinant Jak2, Src, STAT3, and 
STAT5 proteins with and without Src and Jak2 pharmacologic inhibitors.  We also 
examined the interactions of these proteins in intact HNSCC cells.  We found that 
recombinant Jak2, STAT3, and STAT5 are direct substrates of Src and that 
recombinant Src, STAT3, and STAT5 are direct substrates of Jak2 in the IVKA.  To 
our knowledge, the finding that Src is a Jak substrate is novel and has not been 
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shown before. In intact HNSCC cells we find that STAT3 can be reactivated despite 
continuous Src inhibition and that STAT5 continues to be inhibited despite Jak2 
reactivation. Also, Jak2 inhibition did not affect Src or STAT5 activity but it did cause 
STAT3 inhibition. We hypothesized that the differences between the intact cells and 
the IVKA assays were due to a potential need for binding partners in intact HNSCC 
cells.   One potential binding partner that we examined is the epidermal growth 
factor receptor (EGFR). We found that EGFR activation caused increased activation 
of Src and STAT5 but not Jak2. 
Our results demonstrate that although STAT3 and STAT5 are capable of 
being Src and Jak2 substrates, in intact HNSCC cells Src predominantly regulates 
STAT5 and Jak2 regulates STAT3.  Regulation of STAT5 by Src may involve 
interactions between Src and EGFR. This knowledge along with future studies will 
better define the mechanisms of STAT regulation in HNSCC cells and ultimately 
result in an ideal combination of therapeutic agents for HNSCC. 
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CHAPTER 1: INTRODUCTION 
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Head and Neck Squamous Cell Carcinoma Background 
Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most 
common type of cancer worldwide (1). Approximately 3 to 5% of patients in the 
United States (US) with cancer suffer from HNSCC. It is estimated that in the US 
about 53,640 people will acquire head and neck cancer in 2013 and of these, 
11,520 people will die. Generally, twice as many men suffer from HNSCC as 
women and a majority of people are diagnosed after the age of 50. This type of 
cancer begins in the squamous cells that line the head and neck mucosal surfaces 
(2). These surfaces include those of the pharynx, larynx, oral cavity, paranasal 
sinuses, and nasal cavity (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Anatomy of the Head and Neck. Permission to use this image was 
given by Ms. Terese Winslow LLC.  
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Many risk factors can contribute to HNSCC. About 85% of head and neck 
cancers are caused by tobacco use. Human papilloma virus (HPV), particularly 
subtypes 16 and 18, is a major risk factor for oropharyngeal cancer; the incidence of 
HPV-related oropharyngeal cancer is increasing in the US (3). Other risk factors 
include alcohol consumption, exposure to the sun (lip), Epstein-Barr virus 
(nasopharynx), male gender, advanced age, Asian race, poor oral hygiene, and 
others (4, 5).  
The choice of treatment depends principally on the location of the primary 
tumor and the stage of the cancer. Treatments include surgery, targeted therapy, 
radiotherapy, chemotherapy, or a combination of these therapies. All of these 
therapies can result in uncomfortable and life-altering side effects that may impact 
speech, eating, hearing, vision, and appearance. For example, surgery may result 
in the removal of the larynx (voice box); radiation therapy can cause hypothyroidism 
and severe xerostomia by destruction of the normal thyroid and salivary tissue 
respectively; chemotherapy can enhance the effects of radiation and can also cause 
systemic side effects such as infection, hair loss, fatigue, neuropathy, nausea and 
vomiting (2). 
Targeted therapy inhibits specific proteins that allow the cancer cells to grow 
and survive; there is a continuous need for research to identify specific targets so 
that inhibitors or other treatments can be used against them. Cetuximab, a 
monoclonal antibody against epidermal growth factor receptor (EGFR) is the only 
currently approved targeted therapy against HNSCC (6).  Cetuximab is used in 
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combination with chemotherapy or as monotherapy for metastatic disease or in 
combination with radiotherapy for locally advanced HNSCC. 
 
Commonly altered signaling pathways in HNSCC 
Targeted therapy is an important and effective way in which cancer patients 
are treated. For targeted therapy to be effective, it is essential to know which 
signaling pathways are activated and drive cancer survival and progression in a 
specific type of cancer. Previous research has shown that several signaling 
pathways may contribute to the progression of HNSCC.  
EGFR has been targeted for the treatment of HNSCC and other cancer 
types.  In non-small cell lung cancer (NSCLC) EGFR may be activated through 
mutation. Although activating mutations in EGFR are rare in HNSCC, EGFR is 
overexpressed, often by gene amplification, in this type of cancer in 80-90% of all 
cases (7). EGFR is a transmembrane glycoprotein that is part of the ErbB/Her 
family of tyrosine kinase receptors. When EGFR binds its ligand such as Epidermal 
Growth Factor (EGF) or transforming growth factor  (TGF), the receptor 
experiences a conformational change that exposes two previously occluded sites 
within EGFR and allows dimerization with another EGFR or ErbB/Her family 
member. Receptor dimerization allows EGFR autophosphorylation and the 
activation of its kinase activity.  EGFR has several substrates which subsequently 
cause activation of downstream pathways that are involved in proliferation, survival, 
and migration of the cancer cell.  One of the best-studied pathways downstream of 
EGFR and other cell surface receptors is the RAS/RAF/MAPK pathway. Previous 
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studies have shown that EGFR overexpression in HNSCC correlates with poor 
clinical outcome (8); EGFR tyrosine kinase inhibitors have been approved for 
clinical use and include gefitinib, erlotinib, and lapatinib (1, 9).  
Another important signaling pathway in HNSCC is the PI3K/Akt/mTOR 
pathway.  It has been discovered through whole-exome sequencing that about 20-
30% of HNSCC tumors that were analyzed had activating mutations in 
phophoinositide 3-kinase (PI3K) (10). Class IA PI3Ks are a family of kinases that 
phosphorylate phosphatidylinositols such as phosphatidylinositol-4,5,bisphosphate 
(PI(4,5)P2) to produce phosphatidylinositol-3,4,5,trisphosphate (PI(3,4,5)P3), which 
is a second messenger. This second messenger then binds to 3′-phosphoinositide-
dependent kinase 1 (PDK1) at the Plekstrin Homology (PH) domain and Akt.  This 
binding causes their translocation to the cell membrane and allows PDK1 to 
phosphorylate and activate Akt. Activated Akt has multiple substrates, including 
mTORC1, that are necessary for many cellular processes such as cell survival 
(Figure 2). This pathway becomes constitutively active when there is an activating 
mutation in the PIK3CA gene. Mutations can also occur in other parts of this 
pathway including Akt, other PI3K family members, and PTEN, a phosphatase 
which acts to inhibit Akt by dephosphorylating (PI(3,4,5)P3).  Components of this 
pathway can be altered by mutation, deletion, amplifications, and loss (11). 
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Figure 2. The PI3K/Akt pathway and common mutations. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews: Drug Discovery. Faivre, 
S., G. Kroemer, and E. Raymond. 2006. Current development of mTOR inhibitors 
as anticancer agents. Nature reviews. Drug discovery 5:671-688. 2006.  
 
Other commonly activated pathways in HNSCC are Src and the JAK/STAT 
pathways described in more detail below.  Common somatic mutations include 
those in FAT1, HRAS, MLL2, CASP8, FBXW7, and CDKN2A (12). Several tumor 
suppressors are also commonly mutated in HNSCC and these include p53 and 
NOTCH1(12). 
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Src Family Kinases in HNSCC 
Src belongs to a family of non-receptor tyrosine kinases that includes Yes, Fyn, Lyn, 
Lck, Blk, Fgr, and Hck in mammals. Src was the first proto-oncogene to be 
discovered and is an important protein that has roles in cancer cell migration, 
proliferation, survival, differentiation, invasion and angiogenesis (13).  
 
 
Figure 3. Src kinase structure showing all domains. Reprinted by permission 
from Macmillan Publishers Ltd: Oncogene, 2004.  
 
The Src protein has several domains that contribute to and regulate its 
function as a kinase. Src contains a catalytic domain (SH1 domain), SH2 domain, 
SH3 domain, SH4 domain, and a unique domain (Figure 3).  The catalytic domain 
or kinase domain (SH1) contains an activation loop where the tyrosine 419 
(humans) is located. Src kinases also have a small C-terminal cytoplasmic tail, 
which contains a phosphorylation site at tyrosine 527. This is an inhibitory 
phosphorylation site. The SH2 and SH3 domains are non-catalytic domains that 
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together act as a regulatory unit. These two domains allow Src to be in an inactive 
confirmation when there is intramolecular binding (13). (Binding of the Src SH2 
domain to phosphopeptides is determined by residues in both the SH2 domain and 
the phosphopeptides). The SH2 and SH3 domains allow for the recognition of other 
proteins to bind to Src via phosphotyrosine motifs and proline-rich motifs and once 
this binding occurs, the protein unfolds and becomes activated because the kinase 
phosphorylation site is accessible (Figure 4) (14). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Active and Inactive conformations of Src. Reprinted from Molecular 
Cell, Vol 3, Weqing Xu, Amish Doshi, Ming Lei, Michael J Eck, Stephen C Harrison, 
629-638., 1999, with permission from Elsevier.  
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There is increased Src expression in HNSCC compared to the normal 
mucosal surfaces (15). Previous reports have also shown that Platelet Derived 
Growth Factor Receptor (PDGFR), EGFR, and Focal Adhesion Kinase (FAK), 
among many other molecules, can activate Src (16-20). There has also been 
evidence to suggest that the cytoplasmic domain of beta integrin may have a role in 
Src activation (21). The integrins are described in more detail below.  
Src directly phosphorylates many proteins. Its substrates include STATs, cell 
adhesion receptors, G-protein coupled receptors, Hepatocyte growth factor receptor 
(Met), and components of the FAK, PI3K-Akt, MAPK, and Jak/STAT pathways (22-
25).  It is known that Src activates STATs, particularly STAT3 and STAT5, 
independently of Jak activation (26). Previous reports from this laboratory also show 
that with Src inhibition, both STAT5 and STAT3 are initially inhibited (27). 
Integrins 
As mentioned previously, integrins act upstream of Src. Integrins are needed 
for cell adhesion to the extracellular matrix, which is important for cell survival, 
differentiation, growth, migration, etc. Integrin signaling occurs through the 
interaction of protein partners such as FAK, adaptor proteins, and integrin-like 
kinase (ILK). Integrins are made up of an α chain and a β chain. There are 18 α 
chains and 8 β chains. One of the most common chains found in integrin 
heterodimers (in epithelial cells) is the β1 integrin. Cytoplasmic proteins and adaptor 
proteins bind to the cytoplasmic tails of integrins, which leads to signaling (28). 
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The Jak-STAT pathway 
 The main components of the Jak/STAT pathway include a cytokine or growth 
factor receptor, Janus Kinases (Jaks) and Signal Transducers and Activators of 
Transcription (STATs). Janus Kinases (Jaks) are a family of non-receptor tyrosine 
kinases; this family includes Jak1, Jak2, Jak3, and Tyk2. A diagram of the Jak 
structure is shown below (Figure 5). Jaks contain 7 Jak Homology (JH) domains.  
The JH1 domain, which is at the C-terminal end, is also the catalytic domain. This 
domain contains phosphotyrosines that are necessary for the activation of Jaks 
(tyrosine 1007/1008 for Jak2). The JH2 domain is the “pseudo-kinase” domain. This 
domain acts to negatively regulate the protein; when tyrosines on this domain are 
phosphorylated, the activity of the JH1 domain is inhibited. JH3 through JH7 
domains are also regulatory domains and are needed for receptor interactions and 
includes the FERM (F -4.1 protein, E -ezrin, R - radixin and M – moesin) domain 
(29).  
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Figure 5. Structure of Jak Kinase. (a) shows the main Jak domains and (b) shows 
the Jak homology domains. Reprinted from Trends in Molecular Medicine, Vol 11, 
Chloe James, Valerie Ugo, Nicole Casadevall, Stefan N. Constantinescu, William 
Vainchenker, A JAK2 mutation in myeloproliferative disorders: pathogenesis and 
therapeutic and scientific prospects, 546-554, 2005, with permission from Elsevier.  
 
 
 
 
The Jak/STAT pathway is primarily activated by cytokine and growth factors. 
When the receptor’s ligand binds, receptor dimerization occurs to form homodimers 
or heterodimers allowing the associated Jaks to trans-phosphorylate each other to 
become activated, which then allows them to phosphorylate the interacting 
receptors and STATs. Phosphorylation of STATs causes them to dimerize and 
translocate to the nucleus, where they can bind to specific DNA sequences and 
cause transcription of their target genes (Figure 6) (30). 
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Figure 6. The Jak-STAT pathway. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Immunology. Shuai, K., and B. Liu. 2003. 
Regulation of JAK-STAT signalling in the immune system. Nature reviews. 
Immunology 3:900-911. 2003.  
 
 
The STAT proteins are transcription factors that regulate cell survival and 
differentiation. There are 7 STAT family members which are STAT1, STAT2, 
STAT3, STAT4, STAT5A, STAT5B, and STAT6. Unphosphorylated STATs are 
located in the cytoplasm.  After phosphorylation they dimerize through the 
interactions of their SH2 domains and move to the nucleus where they bind to 
specific sequences on the DNA called Gamma-activated sites (GAS) and stimulate 
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transcription (31) (Figure 7). The two STAT family members that are implicated in 
HNSCC progression are STAT3 and STAT5 (32, 33). STAT3 is activated principally 
through phosphorylation of tyrosine 705 and this activation results in its mediation of 
important cell processes such as cell proliferation and apoptosis. STAT5 has two 
isoforms, STAT5A and STAT5B and they are activated by phosphorylation of 
tyrosine 694.  
 
 
 
 
 
 
Figure 7. STAT structure showing different domains and their functions. 
Reprinted from The Jounal of allergy and clinical immunology, Vol 119, Weiguo 
Chen,Gurjit K. Khurana  Hershey, Signal transducer and activator of transcription 
signals in allergic disease, 2007, with permission from Elsevier.  
 
This pathway can be regulated at several levels. For the negative regulation 
of this pathway, there are three types of negative regulators. These include the 
Suppressor of Cytokine Signaling (SOCS) proteins, protein inhibitors of activated 
STATs (PIAs), and Protein Tyrosine Phosphatases (PTPs). SOCS inhibit the kinase 
activity of Jaks, aid with ubiquitin-mediated degradation, and prevent STATs from 
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binding to cytokine receptors. The PIAs negatively regulate STAT transcription and 
PTPs dephosphorylate Jak kinases (27). Although this pathway has been 
researched extensively, there are still many details of the pathway that are 
unknown. 
 
STAT3 Reactivation Following Sustained Src Inhibition in HNSCC 
 Previous studies have shown that Src inhibition using an ATP-competitive 
Src kinase inhibitor such as dasatinib results in rapid (30 min) Jak2, STAT3, and 
STAT5 dephosphorylation and inactivation (27). During sustained Src inhibition, 
decreased STAT3 activation is only temporary but STAT5 inhibition was sustained.  
By 4-7 hours STAT3 becomes reactivated. This is also similar to Jak2 in that 
sustained Src inhibition results in initial Jak2 inhibition and Jak2 kinase activity 
recovers by 7 hours. In a previous study, it was shown that STAT3 reactivation 
occurs via Jak2 kinase activity and Jak-STAT3 binding. The investigators showed 
that when they depleted Jak2, they also saw an inhibition of STAT3 (Figure 8) (27). 
Because Jak2 regulates STAT3, when Jak2 is chronically inhibited so is STAT3 
(Figure 8) (27). 
 The reactivation of STAT3 is dependent upon Jak2 and Tyk2. This was 
shown by depleting both Jak2 or Tyk2 using siRNA. Depletion of Tyk2 or JAK2 
caused a partial decrease in STAT3 reactivation after Src inhibition. When both 
Jak2 and Tyk2 were knockdown at the same time, there was complete inhibition of 
STAT3 reactivation (27).  
 The reactivation of STAT3 and Jak2 is biologically important. When STAT3 
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was completely abrogated along with Src, there was significant cell cycle arrest. 
There was also an increase in apoptosis when cells were treated with both a Src 
inhibitor and STAT3 siRNA compared to when cells were just treated with the Src 
inhibitor. This suggests that STAT3 and Src work together to maintain cell survival 
and proliferation and that STAT3 reactivation lessens the effects of Src inhibition on 
cancer cell survival and proliferation.  
The reactivation of Jak2, Tyk2, and STAT3 is due to the loss of SOCS2 
expression. STAT5 regulates SOCS2 transcription (34). The loss of STAT5 activity 
following Src inhibition leads to the decrease of SOCS protein levels.  This prevents 
SOCS2 from inhibiting Jak2, interfering with Jak2-STAT3 binding and Jak2 kinase 
activity.  
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Figure 8. Schematic of basal, acute, and chronic Src inhibition and its effect 
on Jak2 and STAT activation. The basal state shows activation of Src, Jak2, 
STAT3, and STAT5. Acute Src inhibition results in inhibition of Jak2, STAT3, and 
STAT5 activity. Chronic Src inhibition results in STAT3 and Jak2 reactivation and 
durable STAT5 inhibition. In a negative feedback pathway, SOCS binds to and 
inhibits Jak2 from binding to STAT3. Taken from Courtney Nicholas with 
permission, PhD. 
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Hypothesis 
The model described above provides a framework for a feedback loop in 
which the inhibition of Src leads to Jak, STAT3, and STAT5 inhibition.  The 
sustained inhibition of STAT5 leads to the loss of SOCS2 transcription.  The 
decrease of SOCS2 protein levels allows for Jak2 and STAT3 reactivation by 
removing an inhibitory effect on Jak2-STAT3 binding and Jak2 kinase activity.  
However, this model has several unanswered questions. 
Although we know that Src inhibition leads to Jak2, STAT3, and STAT5 
inhibition, we do not know if these molecules are direct substrates of Src. We are 
also uncertain about how STAT5 and STAT3 are regulated within the cells. We 
hypothesize that they are regulated independently by Src and Jak2 respectively. We 
also do not know the primary regulator of Src in HNSCC cells. It is possible that 
EGFR, FAK, integrins, a combination of these, or other upstream pathways may 
regulate Src activation in HNSCC.  
This thesis examines these questions by manipulating the pathway by use of 
inhibitors and stimulation using recombinant cytokines and growth factors. In vitro 
kinase assays were also performed to look at the interaction of Jak2, Src, STAT3, 
and STAT5 in a cell free system to compare these interactions with the interactions 
that occur in intact HNSCC cells. Better understanding of the Jak/STAT pathway is 
essential so that ultimately better treatments can be developed in order to improve 
patient survival and lifestyle.  
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CHAPTER 2: MATERIALS AND METHODS 
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Cells and reagents 
Human HNSCC cell lines OSC19 and TU167 were obtained from Dr. Jeffrey 
Myers, MD Anderson (35). Cell lines were authenticated by DNA fingerprinting and 
tested for mycoplasma and other contaminants by mouse antibody production 
(MAP) testing.  Dasatinib, pyridone 6, saracatinib, PF-00562271, and imatinib were 
purchased from Selleck Chemicals (Houston, TX) and prepared as stock solutions 
of 10 or 100 mmol/L in DMSO. Cytokines and Growth factors (PDGF, IGF, EGF, IL-
6, and TGF-α) were purchased from Peprotech (Rocky Hill, New Jersey). 
Full length human, recombinant His-tagged Src expressed in insect cells (66 
kDa) was purchased from Sigma-Aldrich.  Human, recombinant Jak2 containing the 
JH1 and JH2 domains (amino acids 532-1132, 99kDa) expressed in Baculovirus 
infected Sf9 cells was purchased from Sigma-Aldrich and Invitrogen. Human 
STAT5A was purchased from Novus Biologicals. This recombinant protein contains 
full length STAT5A and a GST tag resulting in a protein of about 115 kDa that was 
expressed in an in vitro wheat germ system. Human STAT3 was purchased from 
Abcam (Cambridge, MA). This protein is a full-length recombinant protein that was 
expressed in Sf9 insect cells and contains an N-terminal GST tag resulting in a 
protein of about120 kDa. 
Antibodies pSrc (Y416) CS2101, total Src CS2110, pJak2(Y1007/1008) 
CS3771, pSTAT3(Y705) CS9131, Total Stat3 CS9139, pSTAT5(Y694) CS9351, 
Total STAT5 CS9358, pEGFR (Y1068) CS3777, total EGFR CS4267, pFAK(Y576) 
CS3281, pFAK(Y925) CS3284, pFAK(Y861) CS3283, total Fak CS3285, total 
PDGFRβ CS3169, and β1 Integrin CS9699 were all purchased from Cell Signaling. 
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pPDGFR(Y572/574)  #44-1000G and pFAK(Y397) #44624G were purchased from 
Invitrogen. Total Jak2 (sc-294) was purchased from Santa Cruz.  Phospho-Paxillin 
was purchased from Abcam 
For immunoprecipitations, the Jak2 antibody (AHO1352) was purchased from 
Invitrogen and the Src antibody (OP07A) was purchased from Calbiochem. 
 
In Vitro kinase assays 
This assay was done as previously described with the following modifications 
(27). Recombinant proteins [Src (435 nmol/L),  Jak2 (870 nmol/L), STAT5 (870 
nmol/L), and/or STAT3 (870 nmol/L)]  were incubated with DMSO control,  2 μM 
saracatinib, 100 nM dasatinib, or 20 mM pyridone 6  for 30 minutes after which HBV 
buffer [50 mM/L HEPES, 100 umol/L sodium orthovanadate (pH 7.4),  1 M/L MgCl2, 
1 M/L MnCl2 and 10 μCi (y-
32P)ATP (3000 Ci/mmol; 1 Ci= 37 GBq)] was added and 
the samples incubated for another 15 min at room temperature. The reaction was 
stopped with 3X sample buffer (2% SDS, 5% beta-mercaptoethanol, 0.125 mol/L 
Tris (pH 6.8), 1 mmol/L EDTA, 0.02% bromphenol blue). The samples were then 
boiled for 5 min and separated on 7.5% SDS-PAGE. The gel was fixed with fixing 
solution [45% Methanol, 45% distilled water, 10% Acetic Acid] for 20 min two times 
and boiled with 1 mol/L KOH for 10 minutes. The gel was then placed back in fixing 
solution for another 20 min and then dried using a gel dryer for 3 hr. The 
radiolabeled proteins were detected by autoradiography. 
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Cell culture 
HNSCC cells were grown in DMEM containing 10% Bovine Serum in a 
humidified CO2 incubator at 37 ° C. They were grown on 100 mm tissue-culture 
dishes in a monolayer. 
 
Western blot analysis: 
Subconfluent HNSCC cells were washed with phosphate-buffered saline 
without calcium and magnesium. The cells were then incubated for 5 minutes with 
trypsin (Sigma-Aldrich) and spun down for 5 min at 13000 rpm at 4 ° C. The cell 
pellet was washed with PBS and lysed using lysis buffer containing 50 mmol/L 
Trizma base (pH8; Sigma), 1 % Triton X-100, 150 mmol/L NaCL, 20 ug/mL 
leupeptin, 10 ug/mL aprotinin, 1 mmol/L pehnylmethylsulfonyl fluoride, 1 mmol/L 
sodium vanadate and Protease and phosphatase inhibitors and were incubated for 
20 mins at 4 degrees on a rotator.  The lysates were centrifuged for 10 minutes at 
14,000 rpm and the supernatant was collected. The protein concentration of each 
sample was determined using BCA reagents as per manufacturer’s instructions 
(Thermo Scientific).  Equal amounts of each sample was taken and mixed with the 
same volume of 2X sample buffer and resolved by SDS-PAGE and transferred to 
nitrocellulose membranes.  The membranes were blocked in 5% milk in TBS-T for 1 
hr at room temperature and then probed with primary antibody overnight.  The 
primary antibody was incubated overnight at 4°C and then the membrane was 
washed with TBS-T 3 times for 5 min. The secondary antibody conjugated with 
horseradish peroxidase in 5% milk in TBS-T was then added for 1-2 hr at room 
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temperature and the membrane was washed again with TBS-T 3 times for 5 min. 
Protein bands were detected using Enhanced chemiluminescence reagent (Pierce). 
 
Immunoprecipitation: 
Tu167 and OSC19 cells were collected and lysed using immunoprecipitation 
(IP) lysis buffer (20 m M Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% NP-40, 5% glycerol). Lysates containing 800 μg of protein were pre-cleared 
using protein A and G sepharose beads for 1 hour.  The cleared lysate was 
incubated with the indicated antibody or IgG control antibody and agarose beads for 
an hour.  The beads were then washed 3 times using IP lysis buffer. Sample buffer 
was added to each sample and then each sample was boiled for 5 min and loaded 
onto SDS-polyacrylamide gels, transferred to nitrocellulose membranes, and probed 
with primary antibodies as indicated. The secondary antibody conjugated with 
horseradish peroxidase was then added and detected using enhanced 
chemiluminescence reagent. 
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Commercially available anti-phosphotyrosine antibodies bind non-specifically  
 
to recombinant Jak2 and Src 
 
To facilitate our research examining Src, Jak, and STAT interactions and to 
enhance lab safety, we attempted to develop an in vitro kinase assay (IVKA) using 
recombinant purified proteins, Src and Jak2, and non-radiolabeled ATP.  
Recombinant Jak2 and Src were incubated with the Src inhibitor, dasatinib, the Jak 
inhibitor, pyridone 6, or vehicle control for 30 min in the presence of 80 mM ATP 
and the exogenous substrate enolase.  Following incubation, the samples were run 
on SDS-PAGE and the membrane was probed with one of two phospho-tyrosine 
antibodies (4G10 or pY100). We did not observe a significant band corresponding 
to enolase.  When Src was incubated with dasatinib, there was no reduction in the 
staining of the 60 kDa band corresponding to Src. Likewise, when Jak2 was 
incubated with pyridone 6; there was no reduction of the 130 kDa Jak2 band (Figure 
9A, B). To investigate the possibility of the recombinant proteins already being 
phosphorylated prior to performing the assay, a phosphatase, protein-tyrosine 
phosphatase 1B (PTP1B), was added to the IVKA reaction mixture without the 
addition of ATP. The results of this assay were similar to the previous one, showing 
no reduction in the staining of both the Src and Jak2 bands (Figure  9C). 
To examine the efficacy of the phosphatase, we immunoprecipitated 
epidermal growth factor receptor (EGFR) from TU167 cells with and without the 
addition of exogenous EGF to stimulate phosphorylation of EGFR. After the 
immunoprecipitation was performed, PTP1B was added to one sample to 
dephosphorylate the receptor.  The lysates were run on SDS-PAGE. The 
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membrane was then probed with pEGFR (Y1068).  As expected, EGF stimulation 
led to a significant increase in pEGFR.  There was no pEGFR band in the sample 
containing EGF and the phosphatase, indicating that PTP1B dephosphorylated 
EGFR (Figure 9D).  We concluded that the phospho-tyrosine antibodies were non-
specifically binding to the recombinant proteins, making this non-radioactive IVKA 
unusable with currently available reagents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Anti-phosphotyrosine antibodies bind non-specifically to 
recombinant Jak2 and Src.   Potent Src (100 nM dasatinib) and Jak (5µM 
pyridone 6) inhibitors did not reduce the staining of Src and Jak2 with the anti-
phospho tyrosine antibodies 4G10 (A) or pY100 (B). PTP1B phosphatase did not 
reduce the staining by 4G10 of the bands corresponding to the recombinant 
proteins (C), but did effectively dephosphorylate EGFR immunoprecipitated from 
TU167 cells (D). 
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Src and Jak2 are direct substrates of each other in a cell-free, in vitro kinase 
assay 
The non-radioactive IVKA was unusable, so the established IVKA method 
was used to explore Src, Jak2, and STAT interactions for the remainder of the 
study. In this method, recombinant proteins are incubated with the Src inhibitor 
dasatinib, the Jak inhibitor pyridone 6, or vehicle control for 30 min in the presence 
of 10 mCi ( -32P)ATP. As expected, Src acted as its own substrate and Src kinase 
activity was inhibited by dasatinib (Figure 10A, lanes 2-3). Likewise, Jak2 was auto-
phosphorylated and its kinase activity was inhibited with pyridone 6 (Figure 10A, 
lanes 5 and 7). Surprisingly, dasatinib also partially inhibited Jak2 in this assay 
(Figure 10A, lane 8) – an effect we had not observed in Jak2 that was 
immunoprecipitated from intact cells incubated with dasatinib (27).  Since dasatinib 
inhibited recombinant Jak2 we used saracatinib, a more specific Src inhibitor, in 
subsequent experiments (Figure 10B-D).                                                                                
When Jak2 was incubated with saracatinib at 200 nM, there was no 
reduction in Jak2 phosphorylation (Figure 10B, lanes 5 and 8), indicating that Jak2 
kinase activity was not being affected by this inhibitor.  However, 200 nM 
saracatinib only partially inhibited Src (Figure 10B, lanes 2-3).  Increasing the 
saracatinib concentration to 2 M led to full Src inhibition (Figure 10C, lanes 1 and 
3) without Jak2 inhibtion (Figure 10C, lanes 2 and 4) 
To determine if Src could phosphorylate Jak2, we incubated the proteins 
together in the presence of pyridone 6.  When Src and Jak2 were incubated 
together, we saw that both proteins were phosphorylated (Figure 10A-C, lane 6).  
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When pyridone 6 was added to the combination, inhibiting Jak2 kinase activity, Jak2 
was still phosphorylated (Figure 10A-B, lane 10).  This demonstrates that 
recombinant Jak2 is a direct Src substrate. 
When 2 M saracatinib was added to the combination of Src and Jak2 
proteins, Src phosphorylation was observed (Figure 10C, lane 9).  The degree of 
Src phosphorylation was similar to that of the Jak2 and Src combination 
demonstrating that Jak2 can phosphorylate recombinant Src. 
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Figure 10. Recombinant Jak2 is a direct Src substrate and Src is a Jak2 
substrate.  Recombinant Src and Jak2 were incubated with 100 nM dasatinib (A), 
200 nM saracatinib (B), 2 µM saracatinib (C), and/or 20 µM pyridone 6 as indicated 
in an IVKA and phospho proteins detected by autoradiography. 
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           Src regulates STAT5 but not STAT3 activity in intact HNSCC cell lines 
Previously published data demonstrated that Src inhibition leads to marked 
and sustained decreased STAT5 phosphorylation despite recovery of Jak2 activity 
after 4-7 h (27, 34). This suggests that Src, and not Jak2, regulates STAT5 activity 
in HNSCC cells.  To examine potential activators of STAT5 further, we treated 
OSC19 and TU167 cells with interleukin-6 (IL-6), epidermal growth factor (EGF), 
dasatinib, pyridone 6, or saracatinib and examined Src and STAT activation using 
Western blotting (Figure 11). 
As expected, IL-6 had no significant effect upon Src phosphorylation; 
dasatinib and 1 µM saracatinib inhibited Src completely; and pyridone 6 did not 
change Src phosphorylation levels. The lower concentration of saracatinib (75 nM) 
did not completely inhibit Src. STAT5 phosphorylation paralleled that of Src but 
STAT3 activation was unaffected by Src inhibition demonstrating that Src regulates 
STAT5 but not STAT3 activity.  
 
Jak regulates STAT3 but not STAT5 in intact HNSCC cell lines  
We found a significant increase in the phosphorylation of STAT3 in IL-6 stimulated 
samples and complete inhibition with pyridone 6.  IL6 and pyridone 6 did not affect 
STAT5 activation (Figure 11). Since pyridone 6 is a pan-Jak inhibitor and IL6 
stimulates Jak2, we concluded that Jak was regulating STAT3 but not STAT5 in 
HNSCC cells.  
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Figure 11. Src predominately regulates STAT5 and Jak predominately 
regulates STAT3 in intact HNSCC cells. TU167 and OSC19 cells were treated 
with 100 ng/ml IL-6 or 10 ng/ml EGF for 5 min; 100 nM dasatinib for 1 h; 5 M 
pyridone 6 for 1 h; or 75 nM or 1 M saracatinib for 1 or 7 h as indicated.  Cell 
lysates were subjected to Western blotting and expression of various proteins was 
measured using the indicated antibodies.  
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STAT5 is a direct substrate of both Jak2 and Src in a cell-free, in vitro kinase 
assay 
In intact HNSCC cells the inhibition of Src reduced STAT5 activation, but Jak 
inhibition did not.   In contrast, others have demonstrated that STAT5 can be 
regulated by Jak family members (36, 37).  We performed an IVKA to determine if 
STAT5 is a direct substrate of Src or Jak2. Recombinant Jak2, Src, and STAT5A 
proteins were incubated with 32P-labeled ATP both with and without dasatinib or 
pyridone 6. Upon incubation of Src and STAT5A, STAT5A was phosphorylated 
indicating that STAT5A can be a direct substrate of Src (Figure 12, lane 2). When 
Src and STAT5A were incubated with dasatinib, the dasatinib inhibited Src kinase 
activity and no STAT5A phosphorylation occurred (Figure 12, lane 3).  When Jak2 
and STAT5A were incubated together, STAT5A was phosphorylated, indicating that 
STAT5A can also be a direct substrate of Jak2 in a cell free system (Figure 12, lane 
4). When Jak2 and STAT5A were incubated with pyridone 6, this inhibitor inhibited 
Jak2 kinase activity so no STAT5A phosphorylation occurred (Figure 12, lane 5).  
 
 STAT3 is a direct substrate of both Jak2 and Src in a cell free, in vitro kinase 
assay 
  Analogous to the experiments above, we performed an IVKA to determine if 
STAT3 is a direct substrate of Src or Jak2. Upon incubation of Src and STAT3, 
STAT3 was phosphorylated indicating that STAT3 can be a direct substrate of Src 
(Figure 13, lane 4). When saracatinib was added, STAT3 phosphorylation was 
inhibited (Figure 13, lane 6). When Jak2 and STAT3 were incubated together, 
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STAT3 was phosphorylated. Likewise, Jak2 phosphorylated STAT3 which was 
inhibited by pyridone 6 (Figure 13, lanes 5 and 7). Although equimolar protein 
amounts were used, the degree of STAT5A and STAT3 phosphorylation by Jak2 
kinase activity was much lower than that caused by Src. 
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Figure 12. STAT5A is a direct substrate of both Src and Jak2. Recombinant 
Jak2, Src, and STAT5A were incubated with dasatinib, pyridone 6, or vehicle control 
as indicated.  The proteins were subjected to an IVKA with 32P-labeled ATP and 
phosphorylated proteins detected by autoradiography. 
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Figure 13. STAT3 is a direct substrate of both Jak2 and Src.  Recombinant 
Jak2, Src, and STAT3 were incubated with dasatinib or pyridone 6 or vehicle control 
as indicated.  The proteins were subjected to an IVKA using with 32P-labeled ATP 
and phosphorylated proteins detected by autoradiography. 
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EGFR activation increases Src and STAT5 activity in HNSCC cells 
Our data suggest that Src predominantly regulates STAT5 in HNSCC cells 
but Jak2 can also phosphorylate recombinant STAT5A, suggesting that substrate 
specificity in intact cells may be regulated by proximity.  Furthermore, since STAT5, 
STAT3, Src and Jak2 are all located primarily in the cytoplasm (C. Nicholas, 
unpublished data) substrate specificity is likely regulated by differential protein 
binding partners.  To determine the upstream activators of Src and STAT5 in 
HNSCC we first examined the effect of EGFR stimulation on their activation 
because it has previously been reported to stimulate Src in HNSCC (38).  As 
expected, we did detect increased EGFR activation in the EGF and TGF-α 
stimulated cells.  Both EGFR ligands led to activation of Src and STAT5 in TU167 
and Osc19 cells although the stimulation was more marked in Osc19 cells (Figure 
11 and 14).  Basal expression of pEGFR (Y1086) was undetectable and not 
affected by stimulation with IL-6 or incubation with dasatinib, pyridone 6 or 
saracatinib (Figure 11). Tyrosine 1086 was examined because it is not a Src-
dependent phosphorylation site (Jak and Grb2-dependent) (39). 
To test for Src and EGFR interactions, we performed a Src 
immunoprecipitation (IP) from HNSCC cells incubated with EGF, TGF-α, or 
saracatinib (Figure 14A-B). In all conditions, Src and EGFR co-immunoprecipitated 
in TU167 cells but this interaction was not detectable in Osc-19 cells.   Interestingly, 
despite robust Src activation detected on the Western blots following EGF and TGF-
 stimulation, this activation was not detected on the IP samples suggesting that the 
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anti-total Src antibody used for the IP was saturated and preferentially bound to 
phosphorylated Src. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. EGFR co-immunoprecipitates with Src in TU167 cells. Src 
immunoprecipitation of cells treated with EGF, TGF-α, saracatinib for 1 and 7 h in 
(A) TU167 cells and (B) OSC19 cells.  
(Y1068) (Y1068) 
(Y1068) 
(Y1068) (Y1068) 
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Focal Adhesion Kinase may regulate Src Activity in HNSCC 
 
To further investigate the upstream activators of Src, we examined the 
effects of FAK activity on Src activation. We treated HNSCC cells with an ATP-
competitive FAK inhibitor, PF-00562271, for 4 hours at different concentrations (100 
nM, 500 nM, 1 µM, and 3 µM). We saw that with increasing doses, there was a 
gradual decrease in Src activity, but this decrease was very minimal (Figure 15). 
Likewise there was also a decrease in pPaxillin, a known substrate of FAK. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. FAK may play a role in Src regulation. TU167 cells were treated with 
increasing concentrations of PF-00562271 and probed with pFAK(Y397), pSrc, and 
pPaxillin (Y118) (A).(B) shows densitometry. 
B.  
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CHAPTER 4: DISCUSSION 
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In this study, we examined the interactions of Jak2, STAT3, STAT5 and Src 
in HNSCC cells. Previous work from our laboratory defined a feedback pathway in 
which sustained Src inhibition led to the loss of STAT5A-driven SOCS2 expression 
which allowed Jak2 kinase and STAT3 activities to recover.  In this work, we 
demonstrated that Jak2, STAT3, and STAT5A are direct substrates of Src in an 
IVKA with purified proteins.  Likewise Src, STAT3, and STAT5A are all substrates of 
Jak2 in an IVKA.  In contrast, in intact HNSCC cells, Src inhibition leads primarily to 
STAT5 inhibition with transient, minimal effects on Jak2 and STAT3.  Jak inhibition 
in intact HNSCC cells does not affect STAT5 or Src activity but does result in 
STAT3 inhibition. The contrast between the IVKA assays with recombinant proteins 
suggests that substrate specificity in intact cells may be regulated by differential 
protein binding partners.  One potential protein that may mediate the interactions 
between these proteins is EGFR and we demonstrated that EGFR activation leads 
to Src and STAT5 activation. 
Jak and Src Interactions 
Previous studies have shown that in intact breast cancer cells, upon 
stimulation, Jak2 and Src bind to each other (40). However, it has not yet been 
shown whether they directly phosphorylate each other. This is the first report in 
HNSCC that investigates a novel relationship between Jak2 and Src. Our in vitro 
kinase assays show that Src is a direct substrate of Jak2 and Jak2 is a direct 
substrate of Src. These results are significant because within intact cells, when Src 
is inhibited, there is initial inhibition of Jak2 activity as well, but Jak2 is recovered 
after some time. However when we inhibit Jak2 in intact cells, we do not find Src 
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inhibition. This leads to the possibility that Jak and Src do not physically interact 
because they bind to distinct scaffolding proteins.   These results demonstrate that 
Jak2 is a direct Src substrate in intact cells but that Src is not a Jak2 substrate.  As 
discussed below, possible reasons for the discrepancies between the IVKAs and 
the intact cells are that the Jak2 protein used in the IVKA is a truncated protein or 
that Src is more easily accessible for phosphorylation by Jak2 in the cell free 
system.  
 
Regulation of STAT3 and STAT5 Activation 
 The STAT family of transcription factors, especially STAT3 and STAT5, 
regulates oncogenic signaling in many different tumor types (41). STATs are Src 
substrates and can mediate Src’s biological effects including proliferation, survival, 
and angiogenesis (42).  In HNSCC cells, c-Src interacts with STAT3 and STAT5 
(co-immunoprecipitation) and Src inhibition results in reduced STAT3 and STAT5 
activation and reduced cell proliferation (43).  Inhibition of STAT3 in HNSCC leads 
to increased apoptosis, decreased proliferation, and decreased tumor size (44, 45).  
STAT3 activation leads to the increased expression of downstream target genes 
(e.g., Bcl-XL, cyclin D1, survivin) and increased cell proliferation and tumor growth 
in vivo (46).  STAT3 is essential for Src-mediated angiogenesis; following activation 
by Src, STAT3 binds to the promoter of vascular endothelial growth factor (VEGF), 
leading to increased VEGF production (47, 48).  Activation of STAT3 is required for 
v-Src-mediated transformation (49) suggesting that STAT3 is a key mediator of the 
oncogenic effects of c-Src.   
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In addition to regulation by Src, STAT3 can be activated by Jaks.  Jaks are 
essential for cytokine signaling.  Jaks constitutively bind to cytokine receptors which 
do not have intrinsic kinase activity.  Upon ligand binding, the cytokine receptor 
undergoes oligomerization resulting in Jak activation by trans-phosphorylation.  The 
activated Jak molecules then phosphorylate the cytokine receptor allowing for the 
binding of the monomeric, inactive STATs that are present in the cytoplasm.  Once 
bound to the cytokine receptors, STATs become Jak substrates.  Phosphorylated 
STATs undergo dimerization and nuclear translocation (42).  The molecular 
mechanisms leading to Jak activation are not fully understood and this simplified 
model understates the complexity of these pathway interactions.  Two key 
examples are that: activation of Jak2 can occur, albeit at a lower level, in the 
absence of Y1007/1008 phosphorylation, theoretically obviating the need for 
activation by an upstream kinase (50); and Jaks can be activated by oncogenic 
tyrosine kinases, independent of cytokine receptors (51-53). There has been 
evidence to suggest that Jak does not activate STAT5. After sustained Src inhibition 
as already mentioned, Jak2 is reactivated. With Jak2 reactivation STAT3 
reactivation was also seen, but STAT5 remained inhibited (27). 
As part of this study we also looked at the regulation of STAT3 and STAT5 
by Src and Jak2. Our results demonstrate that STAT5A can be directly 
phosphorylated by both Src and Jak2 in an IVKA but that in intact HNSCC cells Src, 
but not Jak2, regulates STAT5 activity.  Similarly, we also found that STAT3 can be 
phosphorylated by both Jak2 and Src in an IVKA but in intact cells Jak2 regulates 
STAT3 activity. Another discrepancy between the IVKA and the intact cell data was 
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that the degree of phosphorylation of the STAT proteins by Jak2 was much lower 
than that of Src. There are several possible reasons to explain the discrepancies 
between the two systems.  First a receptor and/or adaptor proteins may be needed 
to complex with Jak2 and STAT3 for STAT3 phosphorylation to occur. This is 
consistent with what we know about how Jak functions in cells.  This complex may 
be needed to affect conformational changes in the involved proteins or simply to 
bring them into proximity for enzymatic interactions.  Another reason for the lower 
Jak2 kinase activity toward STAT3 in the IVKA may be due to the recombinant Jak2 
being a truncated protein. While the domains that we think are the most important 
for kinase activity and regulation, the JH1 and JH2 domains, are still present, the 
recombinant Jak2 lacks the 20 kDa region on the N-terminal end.  This loss may 
affect Jak2 interactions with its substrates. It is also possible that Jak2 may have a 
slower enzyme kinetics or that the accessibility of both Jak2 and Src to the STAT 
proteins may be better In Vitro compared to intact cells.  
When we investigated the regulation of STAT3 and STAT5 in intact HNSCC 
cells, we saw that Jak2 was the primary regulator of STAT3. When Src was 
inhibited with dasatinib and saracatinib, there was no sustained decrease in STAT3 
activity, but when Jak2 was inhibited with pyridone 6, we saw complete inhibition of 
STAT3. When we inhibited Jak2 and looked at STAT5 activation, there was no 
change; whereas when Src was inhibited, there was complete inhibition of STAT5. 
These results suggest that Src primarily regulates STAT5. 
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Src Activation 
 Src participates in several cellular functions in cancer cells including cell 
cycle progression, immune recognition, adhesion, spreading, migration, apoptosis 
regulation, and differentiation (54, 55). Although v-Src, which lacks the C-terminal 
regulatory domain and is constitutively active, transforms fibroblasts (56), c-Src is 
only weakly transforming.  HNSCC cells transfected with a dominant active c-Src 
showed enhanced tumor growth and invasion (57).  Inhibition of c-Src activity using 
both molecular approaches and pharmacologic inhibitors leads to reduced 
anchorage-independent growth (58, 59), proliferation (60, 61), tumor growth in vivo 
(62, 63), invasion, migration (64-71), metastasis (72-76), vascularity (77-79), and 
survival (59).  In HNSCC specifically, inhibition of c-Src leads to decreased 
invasion, migration and proliferation (38, 43, 57, 64, 80).   
Aberrant c-Src expression has been demonstrated in multiple epithelial 
cancers (81) where its expression and activation correlate with malignant 
progression (82-88), advanced clinical stage, and poor survival (89).  c-Src is 
expressed in areas of hyperproliferation in HNSCC, dysplastic oral epithelium, and 
benign oral mucosal lesions (90).  Several Src members are expressed and 
activated in multiple HNSCC cell lines (38, 43, 91).  Expression of activated c-Src is 
higher in human HNSCC tumor tissue than in normal mucosa and correlates with an 
invasive, poorly differentiated phenotype and advanced nodal stage (15). 
Src can be activated by Platelet Derived Growth Factor Receptor (PDGFR), 
EGFR Focal Adhesion Kinase (FAK), G-coupled protein receptors (GCPRs), and 
integrins (16-21). We examined the effect of EGFR on Src activation because 
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previous reports had identified Src and STAT activation downstream of EGFR in 
HNSCC cells.  When we stimulated cells with ligands that are known to activate 
EGFR (EGF and TGF- α) we observed an increase in Src activation. We also 
performed an immunoprecipitation and found Src-EGFR interaction in TU167 cells. 
However the interaction was undetectable in OSC19 cells. We did not detect any 
association between Src and pEGFR (Y1068). These results (TU167) are similar to 
previously published data suggesting that EGFR is involved in the direct activation 
of Src (26).  As previously mentioned, there are many possible activators of Src. We 
also examined FAK in HNSCC and its effect on Src and found that Src activation 
did not change substantially decrease with the use of a potent FAK inhibitor. 
 
Future Directions 
  We know that STAT3 is an important therapeutic target in HNSCC and that 
both STAT3 and STAT5 have distinct biological functions and transcriptional 
profiles. STAT3 activation as mentioned previously, leads to the increased 
expression of downstream target genes that are involved in cell proliferation, cell 
survival, and angiogenesis. These transcriptional targets include Bcl-XL, cyclin D1, 
and survivin (47, 48). STAT5 activation has been mainly examined in hematopoietic 
malignancies and is also involved in the expression of genes that are needed for 
hematopoiesis and cell differentiation (33, 36). One of the purposes of this study 
was to examine the regulation of both STAT3 and STAT5. We hypothesized that the 
regulation of both proteins was differentially regulated by Src and Jak2 and our 
results supported this in intact HNSCC cells.  
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To address the discrepancies between the IVKA results and the signaling 
results in intact HNSCC cells, future studies should include the purification of a full 
length Jak2 protein and kinase-dead Jak2 and Src proteins to use in the in vitro 
kinase assays instead of using the Src and Jak inhibitors. These inhibitors may 
have non-specific effects that could be affecting the interactions and the use of 
these mutated proteins may eliminate this issue.  
Based on the examination of the regulation of STAT3 and STAT5, we 
concluded and hypothesized that a scaffolding protein may be necessary for the 
activation of Src and STAT5. In this study we only looked at FAK and EGFR as 
possible regulators of Src. We could also look at other kinases such as PDGFR, 
fibroblast growth factor receptor (FGFR), erythropoietin receptor, other ErbB 
receptors, and IGFR, which are known activators of Src. 
We could also use non-biased approaches to identify proteins that bind to 
Jak2, STAT5A, STAT3 and Src. These could include performing 
immunoprecipitations to precipitate one of these proteins followed by mass 
spectrometry to identify proteins that may be co-immunoprecipitating. Another non-
biased approach to study proteins that may be involved in STAT3 and STAT5 
regulation may include an siRNA screen in which hundreds of genes can be 
depleted at one time. The cells are then analyzed to examine a specific protein that 
is affected by the loss of these genes and the siRNA can be identified using 
different methods including mass spectrometry. This method will not identify a 
particular scaffold protein, but can narrow down which protein may be necessary for 
the interactions to occur. 
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Several biased approaches could also be used to study the interactions 
between Jak2, STATs, and Src. One example is the proximity ligation assay (PLA). 
This method is a simpler version of a fluorescence resonance energy transfer assay 
(FRET) and involves the use of two affinity probes directed against two proteins of 
interest. If these proteins physically interact with one another, the probes will anneal 
and the ligated products can then be amplified resulting in their fluorescence (92).  
The ultimate goal of cancer research is to prevent cancer or develop 
treatments for cancer patients that increase survival and improve their quality of life     
by defining the mechanisms that underlie cancer cell progression and survival. In 
HNSCC, it is imperative to study the Src/Jak/STAT pathway and the feedback 
pathways that may be activating STAT3. Because a Src inhibitor has previously 
failed in a clinical trial, it is important to study the pathway further so that other 
biomarkers of HNSCC (such as the STATs) can be identified and targeted. 
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